Market research
IVA.PA Inventiva S.A
PA EUR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 653M
- P/E ratio
- Not available
- Analyst target
- 9.77
- Dividend yield
- Not available
- Beta
- 1.0
Profile
Instrument facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- FR0013233012
- Market cap
- 653M
- P/E ratio
- Not available
- Analyst target
- 9.77
- Dividend yield
- Not available
- Beta
- 1.0
About
About Inventiva S.A
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Research context
Inventiva S.A appears in PyInvesting’s Paris Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the IVA.PA discussion.
5 years, 6 months ago
Inventiva S.A is currently in a long term downtrend where the price is trading 2.2% below its 200 day moving average.
From a valuation standpoint, the stock is 308.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1116.4.
Inventiva S.A's total revenue sank by 0.0% to $4M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 143.5% to $-12M since the same quarter in the previous year.
Based on the above factors, Inventiva S.A gets an overall score of 0/5.